FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD)
Clinical trials for FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD) explained in plain language.
Never miss a new study
Get alerted when new FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD) trials appear
Sign up with your email to follow new studies for FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Drug trial aims to halt debilitating muscle loss
Disease control TerminatedThis study tested whether a pill called losmapimod could slow the progression of facioscapulohumeral muscular dystrophy (FSHD), a genetic disease that causes progressive muscle weakness. About 260 adults with FSHD took either the drug or a placebo pill twice daily for 48 weeks to…
Matched conditions: FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD)
Phase: PHASE3 • Sponsor: Fulcrum Therapeutics • Aim: Disease control
Last updated Apr 04, 2026 06:50 UTC
-
Extended drug trial seeks to tame debilitating muscle disease
Disease control TerminatedThis study aimed to check the long-term safety of a drug called losmapimod for adults with facioscapulohumeral muscular dystrophy (FSHD), a condition that weakens muscles. It was an extension of a previous trial, allowing participants to continue taking the drug. The main goal wa…
Matched conditions: FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD)
Phase: PHASE2 • Sponsor: Fulcrum Therapeutics • Aim: Disease control
Last updated Mar 20, 2026 14:47 UTC